Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2273-2289

  Tkaczuk, Katherine H Rak ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

chemotherapy; combination therapy; metastatic breast cancer; resistance; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IXABEPILONE; LAPATINIB; NANOPARTICLE ALUMINUM BOUND PACLITAXEL; PACLITAXEL; PERTUZUMAB; PLACEBO; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; LOADING DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PROTEINURIA; REVIEW; SENSORY NEUROPATHY; SEPSIS; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 74549203565     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.011     Document Type: Review

References (69)

1. Bray F., McCarron P., and Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6 (2004) 229-239
2. National Cancer Institute Surveillance Epidemiology and End Results (SEER). Cancer survival statistics. http://seer.cancer.gov/statistics/types.html#4 Accessed November 19, 2008
3. Robinson B.D., Sica G.L., Liu Y.F., et al. Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15 (2009) 2433-2441
4. Miles D., von Minckwitz G., and Seidman A.D. Combination versus sequential single-agent therapy in metastatic breast cancer. Onrologist 7 Suppl 6 (2002) 13-19
5. Guarneri V., and Conte P.F. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S149-S161
6. Andreopoulou E., and Hortobagyi G.N. Prognostic factors in metastatic breast cancer: Successes and challenges toward individualized therapy. J Clin Onrol 26 (2008) 3660-3662
7. Bernard-Marty C., Cardoso F., and Piccart M.J. Facts and controversies in systemic treatment of metastatic breast cancer. Onrologist 9 (2004) 617-632
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer, v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf Accessed October 21, 2009
9. Guarneri V., and Conte P. Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 14 (2009) 645-656
10. Gonzalez-Angulo A.M., Morales-Vasquez F., and Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608 (2007) 1-22
11. Cianfrocca M., and Gradishar W.J. Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer. J Natl Compr Canc Metw 5 (2007) 673-675
12. Cinieri S., Orlando L., and Colleoni M. Primary systemic therapy on local advanced breast cancer: Where are we going?. Ann Oncol 17 Suppl 7 (2006) vii18-vii21
13. Budman D.R., and Calabro A. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat 74 (2002) 41-46
14. Barbour S.Y., and Crawford J. Hematopoietic growth factors. In: Pazdur R., Coia L.R., Hoskins W., and Wagman L.J. (Eds). Cancer Management: A Multidisciplinary Approach (2007), CMP Healthcare Media, LLC, Lawrence, Kans
15. Lyman G.H., and Shayne M. Granulocyte colony-stimulating factors: Finding the right indication. Curr Opin Oncol 19 (2007) 299-307
16. Conlin A.K., and Seidman A.D. Point: Combination versus single-agent chemotherapy: The argument for sequential single agents. J Natl/ Compr canc Netw 5 (2007) 668-672
17. Fojo T., and Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 18 Suppl 5 (2007) v3-v8
18. Lee F.Y., Covello K., Castaneda S., et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 14 (2008) 8123-8131
19. Roché H.H., Zambetti M., Dalenc M., et al. Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer. J Clin Oncol 26 Suppl (2008) 1058
20. Rivera E. Management of metastatic breast cancer: Monotherapy options for patients resistant to anthracyclines and taxanes [published online ahead of print August 11, 2009]. Am J Clin Oncol. doi: 10.1097/COC.0b013e3181931049.
21. Moreno-Aspitia A., and Perez E.A. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 31 (2009) 1619-1640
22. Barrett-Lee P.J., Dixon J.M., Farrell C., et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20 (2009) 816-827
23. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20 (2002) 2812-2823
24. Albain K.S., Nag S.M., Calderillo-Ruiz G., et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26 (2008) 3950-3957
25. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25 (2007) 5210-5217
26. Hortobagyi G.N., Perez E., Vrdoljak E., et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: Results from two randomized phase III trials. Presented at the American Society of Clinical Oncology Breast Cancer Symposium. Washington, DC (September 5-7, 2008)
27. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23 (2005) 4265-4274
28. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
29. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112 (2008) 533-543
30. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
31. Carroll K.J. Analysis of progression-free survival in oncology trials: Some common statistical issues. Pharm Stat 6 (2007) 99-113
32. Fleming T.R. Issues in the design of clinical trials: Insights from the trastuzumab (Herceptin) experience. Semin Oncol 26 Suppl 12 (1999) 102-107
33. Miles D., Vukelja S., Moiseyenko V., et al. Survival benefit with capecitabine/ docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial. Clin Breast Cancer 5 (2004) 273-278
34. Gemzar (gemcitabine hydrochloride) [package insert] (2006), Eli Lilly and Company, Indianapolis, Ind
35. Fountzilas G., Dafni U., Dimopoulos M.A., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Res Teat 115 (2009) 87-99
36. Eniu A., Palmieri F.M., and Perez E.A. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10 (2005) 665-685
37. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7 (2001) 1429-1437
38. Altmann K.H., Wartmann M., and O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470 (2000) M79-M91
39. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55 (1995) 2325-2333
40. Chou T.C., Zhang X.G., Harris C.R., et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A 95 (1998) 15798-15802
41. Kowalski R.J., Giannakakou P., and Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol [R]). J Biol Chem. 272 (1997) 2534-2541
42. Dumontet C., Jordan M.A., and Lee F.F. Ixabepilone: Targeting beta-III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther. 8 (2009) 17-25
43. Ixempra (ixabepilone) [package insert] (2009), Bristol-Myers Squibb Company, Princeton, NJ
44. Bunnell C.A., Klimovsky J., and Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline [2006 ASCO meeting abstracts]. J Clin Oncol. 24 Suppl 18 (2006) 10511
45. Merlin J.L., Barberi-Heybob M., and Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER-2 expressing human breast cancer cell lines. Ann Oncol. 13 (2002) 1743-1748
46. Herceptin (trastuzumab) [package insert] (2006), Genentech, Inc, South San Francisco, Calif
47. Rayson D., Richel D., Chia S., et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: Current experience and future strategies. Ann Oncol. 19 (2008) 1530-1539
48. Tykerb (lapatinib) [package insert] (2007), Glaxo-SmithKline, Research Triangle Park, NC
49. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [published correction appears in N Engl J Med. 2007;356:1487]. N Engl J Med. 355 (2006) 2733-2743
50. Avastin (bevacizumab) [package insert] (2008), Genentech, Inc, South San Francisco, Calif
51. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65 (2005) 671-680
52. Schneider B.P., Wang M., Radovich M., et al., ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 [published correction appears in J Clin Oncol. 2009;27:3070]. J Clin Oncol. 26 (2008) 4672-4678
53. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 23 (2005) 792-799
54. Sledge G., Miller K., Moisa C., and Gradishar W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer [2007 ASCO meeting abstracts]. J Clin Oncol. 25 Suppl 18 (2007) 1013
55. Traina T.A., Theodoulou M., Dugan U., et al. A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study [2008 ASCO meeting abstracts]. J Clin Oncol. 26 Suppl (2008) 1101
56. Robert N.J., Dieras V., Glaspy A., et al. RIBBON-1: Randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 27 Suppl (2009) 1005
57. Ramaswamy B., Elias A.D., Kelbick N.T., et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 12 (2006) 3124-3129
58. Reed S.D., Li Y., Anstrom K.J., and Schulman K.A. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 27 (2009) 2185-2191
59. Gardner E.R., Dahut W.L., Scripture C.D., et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 14 (2008) 4200-4205
60. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23 (2005) 7794-7803
61. Link J.S., Waisman J.R., Nguyen B., and Jacobs C.I. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7 (2007) 779-783
62. Lobo C., Lopes G., Silva O., and Gluck S. Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother 61 (2007) 5321-5533
63. Roy V., LaPlant B.R., Gross G.G., et al., North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 20 (2009) 449-453
64. Le Q.A., and Hay J.W. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 115 (2009) 489-498
65. Verma S., and Ilersich A.L. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 8 (2003) 232-240
66. Poole S.G., and Dooley M.J. Off-label prescribing in oncology. Support Care Cancer 12 (2004) 302-305
67. American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J Clin Oncol. 24 (2006) 3206-3208
68. Polite B.N., Cirrincione C., Fleming G.F., et al. Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840-Cancer and Leukemia Group B. J Clin Oncol. 26 (2008) 2659-2665
69. Carlson R.W., Moench S., Hurria A., et al. NCCN Task Force Report: Breast cancer in the older woman. J Natl Compr Canc Netw. 6 Suppl 4 (2008) S1-S25